The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and β2glycoprotein 1 (and other proteins)
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Circulating autoantibodies to phospholipids (aPLs), such as cardiolipin (CL), are found in patients with antiphospholipid antibody syndrome (APS). We recently demonstrated that many aPLs bound to CL only after it had been oxidized (OxCL), but not to a reduced CL analogue that could not undergo oxidation. We now show that the neoepitopes recognized by some aPLs consist of adducts formed between breakdown products of oxidized phospholipid and associated proteins, such as β 2 glycoprotein 1 (β 2 GP1). Addition of human β 2 GP1, polylysine, native low-density lipoprotein, or apolipoprotein AI to OxCL-coated wells increased the anticardiolipin antibody (aCL) binding from APS sera that first had been diluted so that no aCL binding to OxCL could be detected. No increase in aCL binding was observed when these proteins were added to wells coated with reduced CL. The ability of β 2 GP1, polylysine, or low-density lipoprotein to be a “cofactor” for aCL binding to OxCL was greatly reduced when the proteins were methylated. Incubation of β 2 GP1 with oxidized 1-palmitoyl-2-linoleyl-[1-14 C]-phosphatidylcholine (PC), but not with dipalmitoyl-[1-14 C]-PC, led to formation of covalent adducts with β 2 GP1 recognized by APS sera. These data suggest that the reactive groups of OxCL, such as aldehydes generated during the decomposition of oxidized polyunsaturated fatty acids, form covalent adducts with β 2 GP1 (and other proteins) and that these are epitopes for aCLs. Knowledge that the epitopes recognized by many aPLs are adducts of oxidized phospholipid and associated proteins, including β 2 GP1, may give new insights into the pathogenic events underlying the clinical manifestations of APS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McNeil, H. P., Simpson, R. J., Chesterman, C. N., & Krilis, S. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4120 · Cited by 1,595
Oxidized Phosphatidylcholines That Modify Proteins
Itabe, H., Yamamoto, H., Suzuki, M., Kawai, Y., Nakagawa, Y., Suzuki, A., Imanaka, T., & Takano, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33208 · Cited by 128
Cited by
Napoli, C., D'Armiento, F. P., Mancini, F. P., Postiglione, A., Witztum, J. L., Palumbo, G., & Palinski, W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119813 · Cited by 1,014
“It should be noted, however, that the monoclonal antibodies used to detect these oxidation-specific epitopes recognize MDA-lysine and 4-HNE-lysine adducts present on a variety of different proteins, and thus are not specific for oxidized apo B (28, 48, 49).”
BackgroundSelf-citationPlatelet-Activating Factor and Related Lipid Mediators
Prescott, S. M., Zimmerman, G. A., Stafforini, D. M., & McIntyre, T. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.419 · Cited by 748
Parameters influencing the stealthiness of colloidal drug delivery systems
Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.039 · Cited by 740
Binder, C. J., Hörkkö, S., Dewan, A., Chang, M.-K., Kieu, E. P., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., & Silverman, G. J. (2003) · Nature Medicine · doi:10.1038/nm876 · Cited by 737
Self-citationShaw, P. X., Hörkkö, S., Chang, M.-K., Curtiss, L. K., Palinski, W., Silverman, G. J., & Witztum, J. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8472 · Cited by 676
Self-citation
Metadata
- Authors
- Hörkkö, S., Miller, E., Branch, D. W., Palinski, W., & Witztum, J. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-09-16
- Volume
- 94
- Issue
- 19
- Pages
- 10356-10361
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2058954135
- Cited by
- 139
- References
- 2
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.